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InvasivenessMicroRNAs (miRNAs) regulate diverse biological processes by inhibiting translation or inducing degradation of
targetmRNAs. miR-145 is a candidate tumor suppressor in colorectal carcinoma (CRC). Colorectal carcinogenesis
involves deregulation of cellular processes controlled by a number of intertwined chief transcription factors, such
as PPARγ and SOX9. Since PPAR family members are able to modulate complex miRNAs networks, we hypothe-
sized a role of miRNA-145 in the interaction between PPARγ and SOX9 in colorectal carcinogenesis.
To address this issue,we evaluated gene expression in tissue specimens of CRC patients andwe took advantage of
in vitro models represented by CRC derived cell lines (CaCo2, SW480, HCT116, and HT-29), employing PPARγ
activation and/or miRNA-145 ectopic overexpression to analyze how their interplay impact the expression of
SOX9 and the development of a malignant phenotype.
Results: PPARγ regulates the expression of miR-145 by directly binding to a PPAR response element (PPRE) in its
promoter at−1207/−1194 bp from the transcription start site. The binding is essential for miR-145 upregula-
tion by PPARγ upon rosiglitazone treatment. Ectopic expression of miR-145, in turn, regulates SOX9 expression
through the binding to speciﬁc seed motifs. The PPARγ-miR-145-SOX9 axis overarches cell cycle progression,
invasiveness and differentiation of CRC derived cell lines.
Together, these results suggest that miR-145 is a novel target of PPARγ, acts as a tumor suppressor in CRC cell
lines and is a key regulator of intestinal cell differentiation by directly targeting SOX9, a marker of undifferenti-
ated progenitors in the colonic crypts.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-related
death worldwide, representing the third most common cancer in male
and the second in female subjects. Its incidence is steadily increasing
in many transition and developing countries when compared to the
United States and other western countries. This appears to be due to
the diffusion of unhealthy western lifestyles, such as smoking habit,
physical inactivity and high calorie diets [1,2]. CRC arises from the
intestinal epithelium, which is constantly self-renewing in the cryptsnza” Hospital, Viale Cappuccini,
6281; fax: +39 0882 410271.
).of Lieberkühn, and requires a high rate of cell division to maintain epi-
thelial homeostasis [3]. Activation of the Wnt pathway is the key factor
that controls crypt cells proliferation [4]. In particular, genes that are
members of the Wnt signaling pathway, such as β-Catenin (CTNNB1)
and SRY-box containing gene 9 (SOX9), are crucial for the maintenance
of undifferentiated progenitors in the crypts and for the preservation of
the post-mitotic Paneth cells [3]. Another important factor that plays a
regulatory role in the differentiation process of intestinal epithelial cells
is Peroxisome Proliferator-Activated Receptor gamma (PPARγ) [5].
PPARγ is a member of the nuclear receptor superfamily of ligand-
activated transcriptional factors and is expressed throughout the gastro-
intestinal epithelium. It is becoming increasingly clear that mutations in
developmentally regulated genes and transcription factors can cause
CRC initiation and progression, and, on the other hand, represent possible
therapeutic targets. The implication of PPARγ in colorectal carcinogenesis
Table 1
Clinical and pathological features of colorectal cancer patients.
n = 31 %
Age (years):
Mean ± SD 66 ± 13
Gender:
Male/Female 21/10
Tumor location:
Proximala 15 48.4
Distalb 16 51.6
Modiﬁed Dukes staging system
A 1 3.2
B 11 35.5
C 19 61.3
D 0 /
MSI frequency
High 6 20.7
Low 6 20.7
Stable 14 58.6
Missing 5 /
a Cecum, ascending colon, and proximal transverse.
b Distal transverse, descending colon, sigmoid colon and rectum.
Fig. 1. miR-145 expression levels of in colon cancer tissue compared to matched norma
tissue and in colon cancer cell lines. (A) Expression levels of miR-145 in primary tumors
andmatched normal specimens from a cohort of 31 CRC patients.MiR-145 expression levels
of normal tissue are normalized to 1 and represented as a horizontal line. P-values b 0.05
were considered statistically signiﬁcant. (B) Expression levels of miR-145 in
CaCo2, SW480, HCT116 and HT-29 cell lines compared to normal colon tissue. *p b 0.05
**p b0.01, *** p b 0.001.
Table 2
Clinicopathological parameters in CRC patients and relationship with gene expression
levels. Bold data indicate statistical signiﬁcance.
miR-145
n Median Q1 Q3 p Values
AGE (years) b60 8 0.183 0.091 0.218 0.154
60–67 8 0.311 0.260 0.917
68–75 9 0.427 0.240 0.734
N75 6 0.475 0.075 0.846
Gender M 21 0.427 0.205 0.846 0.105
F 10 0.234 0.049 0.265
Tumor Location Proximal 15 0.420 0.208 0.846 0.292
Transverse 2 0.180 0.004 0.357
Distal 14 0.245 0.049 0.734
Grading G1/G2 28 0.381 0.149 0.790 0.349
G3/G4 3 0.208 0.203 0.240
Dukes A 1 0.004 0.004 0.004 0.230
B 11 0.420 0.227 0.535
C 19 0.263 0.164 0.846
D 0 – – –
MSI statusa MSI-H 6 0.058 0.034 0.134 0.009
MSI-L 6 0.317 0.164 0.846
MSS 14 0.381 0.256 0.734
a Microsatellite instability (MSI) analysis was performed using the Bethesda panel of
microsatellite (BAT25, BAT26, D5S346, D17S250, and D2S123) evaluated by means of a
multiplex-PCR and PAGE analysis. Tumors were then classiﬁed accordingly into microsatel-
lite stable (MSS), microsatellite instability-low (MSI-L), and microsatellite instability-high
(MSI-H).
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,is still debated, considering the controversial results of experimental
studies evaluating the effects of its activation in CRC cell lines, animal
models and humans [6–9].
Mounting evidencepinpoints the role of severalmicroRNAs (miRNAs)
in tumorigenesis. MiRNAs are a class of short (21–24 nucleotide [nt]
long), noncoding RNAs that inﬂuence diverse biological functions by
repressing target genes during normal development, as well as during
physiologic and pathologic responses. This regulation is mediated pre-
dominantly by binding to the 3′-untranslated region (UTR) of mRNAs,
resulting in translational inhibition or transcript destabilization [10].
As a result, miRNAs elicit critical changes in gene expression programs,
which have been reported to underlie diverse aspects of biology,
including developmental timing, differentiation, proliferation, cell death,
metabolism, embryogenesis, and oncogenesis [11,12].MiRNAs biogenesis
is tightly controlled in a tissue- and time-speciﬁcmanner [13,14]; howev-
er, the transcriptional regulation of miRNA genes has not been systemat-
ically studied. So far, only few transcription factors, such as p53, nuclear
factor erythroid-2-related factor 2 (NRF2),myogenic transcription factors
and PPARα, have been shown to regulate speciﬁcmiRNAs inmammalian
cells [15–17].
Deploying amiRNA regulatory network analysis on tissue expression
proﬁling of CRC patients we recently identiﬁed miRNA-145 levels as
strongly decreased [14], in accordance with its role as a candidate
tumor suppressor, often downregulated in lung, prostate, liver and gas-
tric cancers [18–24].MiRNA-145 regulates chondrogenesis by repressing
SOX9 expression [25], modulates embryonic stem cell differentiation by
controlling stemness genes KLF4, OCT4, and SOX2 [26], and targets a
number of oncogenes, such as MYC, DFF45 and FLI[15,27,28]. Moreover,
miR-145 reduces the expression of SOX9/ADAM17 eliminating the pop-
ulation of tumor initiating cells in head and neck cancer tissues [29], and
down-regulates IRS1 protein levels hampering the expansion of colon
cancer cells [30]. The expression of miR-145 depends on correct func-
tioning of p53 signaling pathway [31]. Nevertheless, the mechanisms
underlying miR-145 regulation in the frame of colorectal cancer are
elusive.
We have previously highlighted an important interaction between
PPARγ and SOX9 in a gene regulatory network implicated in colorectal
Fig. 2. Interactions between variables performed by Pearson's product moment correlation
on values normalized by logarithmic transformation. (A) Pearson's correlation test demon-
strates signiﬁcant correlation between miR-145 and SOX9 in complete set of CRC patients.
(B) No signiﬁcant correlation between miR-145 and PPARγ in complete set of CRC patients
was found using Pearson's correlation coefﬁcient test. Statistical signiﬁcancewas determined
by aMann–Whitney test. p=p value; R= Pearson's correlation coefﬁcient; N= number of
CRC patients; and *p b 0.05.
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subcellular localization [9]. The molecular mechanisms underlying their
interaction, however, are still unclear. Since miR-145 regulates the
expression of SOX9 during chondrogenic differentiation [25], and PPAR
family members are gatekeepers of the expression of speciﬁc miRNAs
such as the let-7c and the mir-17-92 cluster [16], we hypothesized
that PPARγ could inhibit SOX9 in a miRNA-145 dependent manner in
colorectal cancer cells.
To address this issue, we evaluated gene expression in tissue
specimens of CRC patients and we took advantage of an in vitro model
represented of PPARγ activation and/or miRNA-145-overexpression in
CRC derived cell lines. The results show for the ﬁrst time that miRNA-
145 is a target of PPARγ and in turn regulates SOX9 expression,
highlighting an important pathophysiological mechanism in the pro-
cess of colorectal carcinogenesis.
2. Material and methods
2.1. Patients
We analyzed primary tumors andmatched normal tissue specimens
from a cohort of 31 CRC patients undergoing curative surgery at our
Institution (21 men and 10 women, mean age ± SD 66 ± 13 years).
Clinical and pathological features of CRC patients are shown in Table 1.
Tissue specimens, collected according to the guidelines of the local
Ethical Committee, were immediately frozen in liquid nitrogen and
stored at−80 °C until nucleic acids and proteins extraction. Written
informed consent was obtained from each patient in accordance with
the Institutional guidelines.
2.2. Cell cultures
CaCo2, SW480, HCT116, and HT-29 cell lines were kept at 37 °C and
5% CO2,maintained in Dulbecco's Modiﬁed Eagle's Medium (DMEM) or
in Minimum Essential Medium (MEM) Alpha Medium supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 ng/ml
streptomycin (Life Technologies Corporation). For rosiglitazone (Ros)
treatment, all cell lines were treated with either vehicle (ethanol) or
20 μM Ros for 24 h.
2.3. Quantitative real-timePCR (qPCR)
Total RNA including small RNA was extracted from human fresh
frozen tissues and colon cancer cell lines using TRIzol Reagent (Life Tech-
nologies Corporation) according to the manufacturer's instructions. For
microRNA detection, 10 ng of RNA were reverse transcribed using the
Taq-Man microRNA reverse transcription kit, including miR145 primers
(Assay ID: 002278) and endogenous control RNU6B (Assay ID: 001093),
in the reaction. Reverse transcription was followed by qPCR assay with
a TaqMan PCR Universal master mix and the appropriate microRNA-
speciﬁc TaqMan probe (Life Technologies Corporation). Expression
levels of miR-145 were normalized to RNU6B and relative expression
levels were calculated within each independent experiment using the
formula 2−ΔΔCT.
2.4. Bioinformatic prediction of miR-145 targets
Putative miR-145 binding sites in PPARG genomic sequence were
predicted by the RNA22 program http://cbcsrv.watson.ibm.com/rna22.
html.
2.5. Reagents
Mouse anti β-Actin, and rabbit polyclonal antibodies directed
against SOX9 were purchased from Santa Cruz (D.B.A., Milan, Italy).PPARγ rabbit monoclonal antibody was purchased from Cell Signaling.
Rosiglitazonewas purchased fromCayman (AnnArbor,Michigan, USA).2.6. Transfection assays
Synthetic miR-145 mimic (MSY0000437, QIAGEN) or miR-145-
inhibitor (MIN0000437, QIAGEN)was transfected into the colon cancer
cell lines and examined at varying concentrations (1–25 nM) using
HiPerfect Transfection Reagent (QIAGEN), following themanufacturer's
instructions. AllStar siRNA (1027280, QIAGEN) was used as negative
control. Transfection efﬁciency was estimated by observing cells using
light microscopy 96 h after transfection and by evaluating miR-145 vs
RNU6B expression levels.
To assess if SOX9 was regulated by miR-145, a miScript Target
Protector (MTP0003089, QIAGEN) designed to bind SOX9 mRNA
(NM_000346) 3′UTR (GTTTTTGTTGAAAACAAACTGGAAACTTGTTTCTTT
TTTT) was used. As negative control, miScript Target Protector that
has no homology to any known mammalian gene (MTP0000002,
QIAGEN), was used. Target protectorswere used to a ﬁnal concentration
of 100 μM.
Fig. 3.miR-145 expression evaluated by qPCR in colon cancer cell lines upon rosiglitazone treatment. Expression analysis by qPCR of miR-145 in HTC116, SW480, HT-29 and CaCo2 cell
lines upon rosiglitazone treatment at concentration of 20 μM for 24 h. *, p ≤ 0.05 value; **, p ≤ 0.01; ***, p ≤ 0.001. Dark gray bars correspond to vehicle treated cells, clear gray bars
correspond to rosiglitazone treated cells.
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CaCo2, SW480, HCT116, and HT-29 cell lines were harvested 48 and
96 h after transfection,washed in PBS, and lysed in RIPA buffer (150mM
NaCl, 50 MTris–HCl, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, at
pH 8). Protein lysates were processed for immunoblotting analyses as
previously described [9].2.8. Expression vectors and mutagenesis
The pCMV6-XL4 plasmid vector (OriGene, Rockville, MD) containing
the PPARγ coding region was used for Cignal™ PPAR (luc) reporterFig. 4.MiR-145 inhibitor transfection and rosiglitazone treatment assay. Expression analysis
of SOX9 in CaCo2, SW480, HCT116 and HT-29 cell lines after transfection with miR-145 in-
hibitor and rosiglitazone treatment at concentration of 20 μM for 24 h, by using qPCR. Trans-
fection of CaCo2 and SW480 cells with miR-145 inhibitor increases SOX9 levels after Ros
treatment compared to control (mock). Apartial rescuewasobserved inHT-29 cells,whereas
in HCT-116 cells an opposite behaviorwas paradoxically displayed, with an increase in SOX9
expression upon rosiglitazone treatment partially counteracted by miR-145 inhibitor.assay (QIAGEN). The luciferase reporter containing the putative miR-
145 promoter in pTransluc vector (P-miR-145) was supplied from
Addgene repository (Plasmid 21496).
A potential PPRE located at−1207 to−1194 bp from the transcrip-
tion start site was identiﬁed in the miR-145 promoter by bioinformatic
analysis (http://www.classicrus.com/PPRE/). AmiR-145 deletion mutant
was then generated by deleting 13 bp spanning the PPRE (AGGCCAAG
GCTCA) and cloned into pTransluc vector (P-miR-145-del). Brieﬂy, this
mutagenesis reactionwas conducted in a total volume of 50 μl containing
100 ng DNA, 5 μl 10× buffer, 125 pmol (ﬁnal) of each primer [For: 5′-
CATTTTATAATTAAAGAGGGGTTAAGTGACTTAC-3′ and Rev: 5′-GTAAGT
CACTTAACCCCTCTTTAATTATAAAATG-3′], 8 μMol (ﬁnal) dNTPs and 1
U Pfu Taq polymerase (Promega) and ampliﬁed using 95 °C × 2 min,
and 18 cycles of 95 °C × 30 s, 55 °C × 1 min and 72 °C × 12 min as PCR
conditions. One μl of Dpn1 (New England Biolabs) was added to digest
parental DNA and 3 μl used to transform DH5α cells (Life Technologies
Corporation). DNA sequencing of colony PCRswere performed to identify
the mutated clone. Plasmid preparation was obtained with Plasmid Midi
Kit (QIAGEN). The empty pTransluc control vector (P-control) was kindly
provided by Dr. K.S. Kosik (MCDB, CSB).
2.9. Luciferase reporter assay
To evaluate the activation of PPARγ transcription factor, the Cignal™
PPAR (luc) reporter assay kit (QIAGEN)was used. Transient transfection
was performed in 96-well plates seeding CaCo2, SW480, HCT116, and
HT-29 cells at a concentration of 2 × 104 cells per well. The cells were
co-transfected using Attractene Transfection Reagent (QIAGEN) with
0.1 μg of pCMV6-XL4-PPARγ expression vector and 0.1 μg of
PPARreporter construct. The PPAR reporter was composed of a mixture
of an inducible transcription factor-responsive ﬁreﬂy luciferase reporter
and a constitutively expressed Renilla construct (40:1). Twenty-four
hours post transfection, cells were treatedwith 20 μMof Ros inmedium
containing 10% FBS for 24 h. Cells were collected and the ratio of ﬁreﬂy
to Renilla luciferase activity was analyzed for PPARγ activity using the
Dual-Glo Luciferase Reporter Assay System (Promega).
Fig. 5. Target protectors assay. CaCo2, SW480, HCT116 and HT-29 cell lines were cotransfected with miR-145 mimic plus a miScript Target Protector speciﬁc for the putative miR-145-
binding site of SOX9 (Mimic + target protector), or solely miR-145 mimic or Negative Control miScript Target Protector. SOX9 mRNA levels were quantiﬁed by qPCR.
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and HT-29 cells were co-transfected with P-miR-145, P-miR-145-del
and P-controlvectors. Brieﬂy, cell lines were seeded in 96-well plates
at a concentration of 2 × 105 cells per well 48 h before the transfection
and then co-transfected with each reporter vector (200 ng/well), 5 ng
of the transfection control Renilla vector (pRL-SV40, Promega) and 0.5
ml of Lipofectamine 2000. The transfected cells were treated with 20
μM of Ros for 24 h. Fireﬂy luciferase/Renilla luciferase ratios were mea-
sured by using the Dual-Glo Luciferase Reporter Assay System.2.10. Statistical analysis
miR-145 expression levels of CRC tissuewere comparedwith those of
adjacent normal mucosa, using the formula 2−ΔΔCt and values were
reported as median, 25th percentile (ﬁrst quartile, Q1) and 75th percen-
tile (third quartile, Q3). For continuous variables normal distributionwas
veriﬁed by the Shapiro–Wilk test and the one-sample Kolmogorov–
Smirnov test. For normally distributed variables, hypotheses regarding
differences among the groups were compared by means of the paired
t-test, Student's t-test or by means of the analysis of variance (ANOVA)
as indicated. For non-normally distributed variables, hypotheses regard-
ing differences among the groups were compared by means of a non-
parametric Wilcoxon signed rank sum test, the Mann–Whitney rank
sum test or the Kruskal–Wallis rank sum test as indicated. Statistical
analyses were also performed on the subjects divided into quartile
groups and by using Pearson's chi-square test to evaluate interactions
between variables. p-Values b 0.05 were considered statistically signiﬁ-
cant. For protein expression levels and in vitro experiments, the results
are expressed as means ± SE. All analyses were performed using SPSS
Statistical Package v17 (SPSS Inc, Chicago, IL, USA).3. Results
3.1. Analysis of miR-145 levels in colorectal tumor tissues and cell lines
We measured miR-145 expression levels by qPCR in 31 paired
tumor-normalCRC tissue samples obtained from the same surgically re-
moved colonic specimens (9). We observed miR-145down-regulation
(median = 0.27, Q1–Q3 = 0.16–0.73, p = 0.0009) in tumor tissues
matched to normal tissues. Median values, 25th and 75th percentile,
and extremes of RNU6B-Ct value/target miR-Ct value are shown in
Fig. 1A. We also correlated miR-145 expression levels with the clinico-
pathological features of the patients: a statistically signiﬁcant relation-
ship was observed between the low miR-145 expression and the MSI
status, in particular with MSI-H (p = 0.005) (Table 2). We then exam-
ined miR-145 expression in four human CRC derived cell lines, CaCo2,
HCT116, HT-29 and SW480: we found a barely detectable level in all
cell lines, when normalized to normal colon tissue (Fig. 1B). To under-
stand the involvement of miR-145 in the interaction of PPARγ with
SOX9, we assessed the correlation between miR-145 expression and
the genes encoding these transcription factors (9). A signiﬁcant inverse
correlation was found between the expression of miR-145 and SOX9
mRNA (Pearson correlation coefﬁcient r = −0.412, p = 0.021)
(Fig. 2A). No statistically signiﬁcant correlation was found between
miR-145 and PPARγmRNA (Fig. 2B).
3.2. PPARγ-inducedmiR-145 targets SOX9
Rosiglitazone-mediated activation of PPARγ induces SOX9 down-
regulation in CRC cell lines (9). Since miR-145 is negatively correlated
with SOX9 expression (Fig. 2A), we hypothesized that the ectopic
expression of miR-145 could inhibit SOX9 expression upon PPARγ
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on miR-145 expression in the four CRC cell lines. Treatment with
rosiglitazone (20 μM) for 24 h resulted in a statistically signiﬁcant
upregulation ofmiR-145 in the cell lines examined (Fig. 3). In particular,
a higher increase was observed in SW480 (3.2-fold, p= 0.01), in CaCo2
(2.6-fold, p = 0.00002), in HT-29 (2.35-fold, p = 0.00003); a lower
ncrease was detected in HCT116 (1.5-fold, p = 0.03). We conﬁrmed
PPARγ activation by rosiglitazone using a speciﬁc Cignal Reporter
assay for PPARγ (Supplementary Fig. 1). Subsequently, to evaluate a
potential role of miR-145 in SOX9 regulation through PPARγ activation,
a loss-of-miR-145 function was applied by transfecting cells with theFig. 6.miR-145 promoter transcription is regulated by PPARγ. Experiments were performed
putative PPAR response element (PPRE) binding site in the promoter of the miR-145 at the l
PPRE, which was deleted in P-miR-145-del. (B) Luciferase assays using P-miR-145p-Luc rep
normalized to the internal transfection control Renilla and then divided by the average value
miR-145 promoter (PPRE) in CaCo2, SW480, HCT116, and HT-29 cell lines. Relative enrichm
experiments, each performed in triplicate (p b 0.05 vs. control).miR-145 speciﬁc inhibitor upon rosiglitazone treatment for 24 h. As
shown in Fig. 4, rosiglitazone treatment signiﬁcantly lowered SOX9
mRNA expression in CaCo2 and HT-29 but not in SW480 and HCT-
116cell lines as we have previously reported [9] (Fig. 4): transfection
with the miR-145 inhibitor induced an increase of SOX9 expression
above control levels in CaCo2 (1.4-fold, p = 0.0007) and SW480 (2.2-
fold, p b0.00001), whereas a partial rescue was observed in HT-29 cells
(Fig. 4). HCT-116 cells paradoxically displayed an opposite behavior,
with an increase in SOX9 expression upon rosiglitazone treatment
[9], partially counteracted by miR-145 inhibitor. Altogether, our re-
sults (Figs. 3 and 4) suggest that miR-145 expression is induced byin transfected CaCo2, SW480, HCT116 and HT-29 cells. (A) Schematic description of the
ocation of−1194 to−1207 bp. The promoter construct P-miR-145 contains a putative
orter. For derivation of the relative luciferase levels, the raw luciferase activity was ﬁrst
of the basal construct P-control. (C) ChIP analysis shows high PPARγ enrichment at the
ent is normalized to control IgG. The data in (B) and (C) were from three independent
Fig. 7. Bioinformatic prediction ofmiR-145 targets,miR-145 transfection assays andWestern blot analysis. (A) PutativemiR-145binding sites in PPARγ genomic sequence predicted by the
RNA22 program. (B) Expression analysis by qPCR of SOX9 in CaCo2, SW480, HCT116 and HT-29 cell lines after transfection with miR-145 mimic at 96 h. (C) Western Blot analysis
performed to evaluate protein levels of PPARγ at 96 h after transfection with miR-145 mimic.
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in CaCo2 and HT-29, but not in SW480 and HCT-116, colon cancer cell
lines.
To test the hypothesis that miR-145 could directly bind SOX9
mRNA 3′UTR and inhibit its expression, we employed miScript
target protectors, which are single-stranded, modiﬁed RNAs that
speciﬁcally interfere with the interaction of a miRNA with a single
endogenous target, leaving unaffected all other targets. We used
miScript target protectors designed for the putative miR-145-
binding site in the SOX9 mRNA 3′UTR. Whereas miR-145 mimic
could efﬁciently downregulate SOX9 mRNA in CaCo2, SW480,
HCT116, and HT-29 cells, co-transfection of the miR-145 mimic
with its target protector was able to reverse the effects of the
miR-145 mimic resulting in increased SOX9 mRNA levels that was
not signiﬁcantly different from the untransfected or negative
control cells (Fig. 5).3.3. Transcriptional regulation of miR-145 by PPARγ
The prerequisite for the transcriptional regulation of a given gene by
PPARγ is the presence of a PPAR response element (PPRE) in the regu-
latory regions [33]. By inspecting miR-145 promoter region, we identi-
ﬁed a putative PPRE (AGGCCAAGGCTCA), located at−1207–1194 bp
(Fig. 6A) from the transcription start site (TSS). To ascertain the func-
tionality of this PPRE as a response element, a 1.5 kb long DNA fragment
corresponding to the promoter regionwas cloned in a luciferase report-
er plasmid, deﬁned P-miR-145. This sequencemotif was thendeleted by
site-directed mutagenesis, generating the plasmid P-miR-145-del
(Fig. 6A). CaCo2, SW480, HCT116, and HT-29 cells were transfected
with P-miR-145 and P-miR-145-del constructs and exposed to 20 μM
rosiglitazone. The transcriptional activity of the plasmid carrying the
wild type promoter increased upon rosiglitazone treatment, while no
variations in luciferase activity were observed with themutant plasmid
Fig. 8. Cell cycle by ﬂow cytometry. Cell-cycle proﬁle was examined by ﬂow cytometry and percentages of cells in G0/G1 (D), S (E), and G2/M (F) phase in CaCo2, HT-29, HTC116 and
SW480 cell lines transfected with miR-145 mimic or inhibitors are indicated in the graphs.
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activation of miR-145 expression in vitro (Fig. 6B). To validate the
binding of PPARγ to miR-145 promoter, we performed chromatinimmunoprecipitation (ChIP; Supplementary Materials and Methods
[32]) analysis in the CRC cell lines. Consistent with PPRE-driven tran-
scriptional activity, rosiglitazone treatment induced PPARγ recruitment
Fig. 9.MTT viability assay at 24, 48, 72 and 96 h in CaCo2, SW480, HTC116 and HT-29 cells transfected with miR145 mimic.
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was used as a negative control (Fig. 6C). These data demonstrate that
miR-145 is a novel PPARγ transcriptional target.
3.4. Prediction and evaluation of miR-145 putative binding sites into
PPARγ gene
Since interlinking positive and negative feedback loops have been
described [15,34] for various miRNAs, we evaluated whether miR-145
was able to regulate PPARγ expression. The RNA22 computational
method was used to predict putative miR-145 binding sites on the
PPARγ gene. An alignment of human PPARγ gene at the predicted
miR-145 binding sites is shown in Fig. 7A. Two putative miR-145 bind-
ing sites located upstream and downstream of the PPARγ gene, were
predicted. To assess if miR-145 targets the putative binding sites in
the PPARγ gene, we performed transfection experiments using speciﬁc
synthetic miRNAs. Transfection was optimized and the efﬁciency deter-
mined after 96 h bymeans of qPCR. Ectopic expression of miR-145 at 96
h did not induce any signiﬁcant change in PPARγ mRNA in any of the
cell lines with the exception of the HT-29 cell line, where we observed
a signiﬁcant down-regulation (FC =−1.4-fold, p = 0.0003) (Fig. 7B).
In this cell line, the same change was also detected at PPARγ protein
level upon ectopic expression of miR-145 (Fig. 7C). Taken together
these data suggest that only in HT-29CRC cell line PPARγ level is bal-
anced by a feedback regulation involving miR-145.
3.5. Effects of miR-145 on cell cycle, cell proliferation and invasiveness in
CRC cell lines
To investigatewhethermiR-145was able to affect cell cycle progres-
sion via SOX9 down-regulation, CaCo2, SW480, HCT116 and HT-29 cell
lines were transfected with a miR-145 mimic or inhibitor for 96 h. In
CaCo2 and SW480 cells transfected with miR-145 mimic as well as
inhibitor we observed an increase of the cells in the G0/G1 phase and
a reduction of those in the S phase when compared to control cells
(Fig. 8). In HT-29 cells transfectedwithmiR-145mimic as well as inhib-
itor an increase in the number of cells in the G2/M phase was observed
when compared with the control cells. Interestingly, miR-145 mimic
transfected HCT116 cells exhibited increase in the number of cells in
sub-GO/G1 phase, an index of pre-apoptosis, and diminution of those
in G0/G1 and S phases when compared with the control cells (Fig. 8).
We then evaluated whether miR-145 could affect cell proliferation by
carrying out the MTT assay at four time points (24, 48, 72, and 96 h)
upon miR-145 mimic transfection. The ectopic expression of miR-145
did not elicit variations in cell growth (Fig. 9). Finally, we investigated
whethermiR-145 could affect cell motility andmigration by performing
the wound-healing and trans-well assay, respectively. A 30% reductionin the ability of the cells to induce wound closure was obtained at 72
h in HT-29, SW480 and CaCo2 cells transfected with the miR-145
mimic, while a 50% reduction was observed in HCT116 cells in compar-
ison with control cells (Fig. 10A). In the trans-well assay, HT-29 cells
transfected with miR-145-mimic showed only marginal reduction in
invasiveness at 72 h, while all the other cell lines examined displayed
a signiﬁcant reduction (about 50%) of invading cells (Fig. 10B). These
data suggest that miR-145 is implicated in the control of cell migration
and motility, features that are indicative of a differentiated phenotype.
To test this hypothesis, we assessed the expression of a series of epithe-
lial and mesenchymal markers upon miR-145over-expression. mRNA
levels of epithelial E-cadherin, CK20 and ZO1were increased, particular-
ly in HCT116 cells (Fig. 10C); in contrast, the mesenchymal markers
Snail, ZEB1, N-cadherin were reduced in all cell lines, suggesting that
miR-145 sustains a differentiated phenotype and counteracts the inva-
sive ability of the cells. Vimentin was signiﬁcantly reduced in SW480
and in HCT-116, and is not expressed in HT-29 and CaCo2. Hematoxylin
and eosin staining showed that miR-145 caused a shift towards more
epithelial morphological characteristics with the tendency to form
cell-aggregates (data not shown).
4. Discussion
Transcriptional regulators play a key role in the process of colorectal
carcinogenesis, and PPARγ is a leading actor in this scenario. Here, we
show that this nuclear receptor transcriptionally regulates in a direct
fashion miR-145, which in turn is a fundamental hinge of cell apoptosis
and differentiation, and is deregulated in CRC. MiR-145 is controlled by
PPARγ and may function as a tumor suppressor directly targeting and
down-regulating SOX9 in colon cancer, inﬂuencing the process of intes-
tinal differentiation at early stage. We found a severe down-regulation
of miR-145 expression in CRC patients, in particular in those with
MSI-H status. Defects in the DNA mismatch repair system are present
in about 15% of CRC patients, leading to MSI and generation of a large
number of substitutions, as well as insertions, deletions, andmutations,
which target microsatellite sequences, resulting in truncation or other
alterations of the protein product. The expression of mRNAs with such
frameshift mutations is reduced by the presence of premature stop
codons and results in degradation of some of themutantmRNA through
the nonsense-mediated decay pathway. In CRC patients, the MSI status
may inﬂuence the response to adjuvant chemotherapy, and in particular
irinotecan-containing regimens assure better outcome in patients
suffering from MSI-H tumors when compared to 5-ﬂuorouracil-
containingtreatments [35]. Furthermore, the signiﬁcant inverse corre-
lation between the decreased expression of miR-145 and the increased
expression of SOX9 suggested that miR-145 and SOX9 are coordinately
regulated in colorectal carcinogenesis. Accordingly, in four CRC derived
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was barely detectable when compared to normal colon tissue, was up-
regulated by PPARγ upon rosiglitazone treatment, and induced SOX9
downregulation by direct interaction.
The results of our experiments convincingly demonstrate that
miR-145 was also able to regulate PPARγ expression by a feedback
mechanism speciﬁcally in the HT-29 cell line, where a cell speciﬁc
transcriptional regulatory mechanism could be envisaged.
MiR-145 upregulation did not change the proliferation ability of
the CRC cell lines, in agreement with data reported in the gastric cancer
cell lines BGC-823, SGC-7901, MKN-45 and MKN-28[22], but not in
the LS174T CRC cell line, where miR-145 reduced proliferation [28].
Variations of themiR-145 levels inﬂuenced cell cycle and induced mor-
phological changes. MiR-145 ectopic expression differently inﬂuenced
cell distribution along the cell cycle in the four CRC cell lines analyzed,
highlighting a cell type-speciﬁc pattern of response despite a common
induced downregulation of SOX9, which plays a fundamental role in
CRC onset and progression [36]. Furthermore, we provided evidence
that miR-145 has a prominent role on cell motility, invasion and epitheli-
al/mesenchymal transition, in agreement with data previously reported
[22]. In particular, Gao and coauthors showed that N-cadherin is a direct
target of miR-145, which was found capable to suppress gastric cancer
cell invasiveness downregulating N-cadherin protein expression through
translation inhibition [22]. Accordingly, in our study over-expression of
miR-145 in HT-29 and HCT116 cells induced signiﬁcant phenotypic
changes towards epithelial features (E-cadherin, CK20 and ZO1 upregu-
lation)while reducingor abolishingmesenchymal stemcell like features
(Snail, ZEB1, N-cadherin and Vimentin). These latter effects are most
likely due to a corresponding decrease of SOX9, a key player of the
WNT/β-catenin pathway involved in the maintenance of crypt stem cell
self-renewal[36]. Consistently, miR145 maintains a differentiated state
by silencingOCT4, SOX2, andKLF4,master regulators of pluripotency [26].
In conclusion, in this study we demonstrated that in colon cancer
cell lines PPARγ activation induces the expression of miR-145, which
in turn modulates the expression of SOX9, inﬂuencing cell-cycle pro-
gression, invasiveness and differentiation status. This newly identiﬁed
molecularmechanism of colorectal malignancymay lead to therapeutic
advancements. In several cancer models the transcriptional activation
of PPARγ through speciﬁc agonists is capable to inhibit cell prolifera-
tion, stimulate terminal differentiation, promote apoptosis and hinder
inﬂammation. On the other hand, PPARγ agonists seem to exert also
pro-tumorigenic effects, and many clinical trials with PPARγ agonists
yielded contrasting results [37]. Modulation of PPARγ signaling path-
way in associationwith othermolecular targetsmight enhance the use-
fulness of the effects induced by chemical or biological agents acting
through this nuclear receptor. Targeting of PPARγ-miR-145-SOX9 axis
brings on physiological effects that could play a chemopreventive or che-
motherapeutic role without the harmful pro-carcinogeneticactions deriv-
ing from the exclusive PPARγ activation.
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